Medical News Today (Free subscription) | 13/09/2008
Results from a new study investigating the benefits of Sativex in neuropathic pain in people with multiple sclerosis (MS) have shown it gave long-term pain relief. The study followed 42 people with MS who took Sativex - a cannabis-based drug trialled by GW Pharmaceuticals.
Financial Time (Free subscription) | 09/09/2008
Shares in GW Pharmaceuticals rose 9 per cent to 48p after the producer of cannabis-based medicines said that its Sativex product yielded long-term pain relief to...
Fiercebiotech (Free subscription) | 08/09/2008
The UK's GW Pharmaceuticals says that its cannabis-based Sativex proved effective as a long-term therapy for MS-related neuropathic pain. Its shares quickly jumped seven percent on the news. GW Release
PharmaGazette (Free subscription) | 18/07/2008
Sativex is a mouth spray derived from marijuana plants. It is one part THC (Tetrahydrocannabinol), the main psychoactive substance found in a cannabis plant, and one part CBD (cannabidiol), the part of the plant that moderates the euphoria and seems to add a sedative effect. GW Pharmaceuticals has begun late stage clinical trials on the buccal spray in both the U.S. and Europe. It was approved in...
The Independent (Free subscription) | 20/06/2008
GW Pharmaceuticals, the UK drug maker that is licensed to use cannabis in its treatments, posted first half numbers yesterday showing narrowed losses.
Medical News Today (Free subscription) | 18/04/2008
GW Pharmaceuticals, which makes Sativex - an oral spray containing a cannabis extract - has released disappointing results of a trial testing the drug's benefits in treating pain in people with multiple sclerosis (MS). The study involved 339 people experiencing neuropathic pain due to MS who have achieved inadequate pain relief with existing therapies.
Financial Time (Free subscription) | 10/04/2008
Shares in GW Pharmaceuticals regained some ground yesterday after the specialist in cannabis-based medicine reported positive results from a Spanish pilot programme to...
Health Business Blog (Free subscription) | 09/04/2008
GW Pharmaceuticals’ marijuana-based drug, Sativex failed to outperform a placebo in a European trial to treat neuropathic pain. The drug probably works, but unfortunately for GW so do placebos. One of our consulting clients is working on tools to identify and characterize patients who are likely to respond to placebos. One potential application is to use [...]
The Independent (Free subscription) | 09/04/2008
Shares in GW Pharmaceuticals lost more than a quarter of their value yesterday after the announcement that a trial of its cannabis-based drug Sativex had failed its final phase of testing.
PharmaGossip (Free subscription) | 08/04/2008
GW Pharmaceuticals has announced its Sativex spray has failed a Phase III pain relief trial among multiple sclerosis patients. The company added that Sativex had a very high patient response rate, but that the results narrowly failed to reach statistical significance because of an unexpectedly large response to a placebo treatment among the test group. "The previous trial yielded a highly significant...
Reuters UK (Free subscription) | 08/04/2008
LONDON (Reuters) - Britain's GW Pharmaceuticals said on Tuesday its pioneering cannabis-based medicine had failed to reach statistical significance in a final stage trial to treat neuropathic pain in multiple sclerosis patients.
Reuters (Free subscription) | 08/04/2008
LONDON (Reuters) - Britain's GW Pharmaceuticals said on Tuesday its pioneering cannabis-based medicine had failed to reach statistical significance in a final stage trial to treat neuropathic pain in multiple sclerosis patients.
